BGI-backed Chinese precision medicine startup Gene+ closes $28m Series B round

BGI-backed Chinese precision medicine startup Gene+ closes $28m Series B round

Next-generation sequencers operate at BGI's five-storey facility in Hong Kong, China, on Monday, Sept. 19, 2011. Photographer: Natasha Khan/Bloomberg

30 September, 2019

BGI Group Co-Stone Asset Management gene technology gene-editing Oncology

Printed by Unregistered user on Fri, 05 Dec 2025 06:47:51 GMT

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief

Subscribe to Newsletter

You may also like

China's BGI Genomics to seek $1b funding ahead of its IPO

China: BGI Genomics completes $250m IPO; Lenovo Capital backs Imsight Medical

Read more from Greater China

Baidu’s Kunlunxin eyes Hong Kong IPO after $283m fundraising

Shares of ‘China’s Nvidia’ Moore Threads soar in debut after $1.1b IPO